Utilizing CXCR1 inhibitors to target CSCs is a promising therapeutic approach with sufficient pre-clinical data to merit examination of their therapeutic efficacy in FOXC1+ pro-metastatic cancers, especially in the setting of advanced/metastatic and/or recurrent cancers which are predicted to be enriched for FOXC1+ CSCs (Figure 5). Here, CXCR1 is linked to cancer.